M&A / Deals UCB cuts $1.15bn deal to buy epilepsy biotech Neurona PharmaphorumUCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.M&A / DealsNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum UCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy. M&A / DealsNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Magazine: Digital twins become the new battleground for CDMOsNext: UCB to purchase Neurona and NRTX-1001 for $1.15bn Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
